
Laplace Intelligence, an Ann Arbor-based startup founded by University of Michigan researchers, is developing automated red-teaming tools for robotics and autonomous vehicles. The company utilizes a simulation environment based on Nvidia’s Cosmos to create interactive physical AI test scenarios, allowing developers to identify safety failures before real-world deployment. Currently generating revenue from customers like Bot Auto and a major Japanese automaker, Laplace aims to establish a trusted evidence base for regulators and insurers as physical AI systems become more prevalent.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
© TechCrunch AIxAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
© TechCrunch AIHugging Face Blog · July 21, 2026 · Related
TechCrunch AI · August 9, 2026 · Related
MIT News AI · August 10, 2026 · Background
NVIDIA Blog · August 11, 2026 · Background
AI Explained · September 4, 2026 · Related
MIT News AI · September 14, 2026 · Related
TechCrunch AI · October 2, 2026 · Related
MIT Technology Review AI · October 8, 2026 · Related
Laplace Intelligence red-teams physical AI in simulation
2 developments
OpenAI is scaling back its ambitions as investor appetite for massive AI infrastructure bets cools. The company has lowered its fundraising target from $30 billion to $20 billion, with only $11 billion secured so far against a valuation that has dropped from $1.4 trillion. This retreat signals a growing wariness among Wall Street investors regarding the capital intensity of the AI race, forcing even the most dominant players to adjust their financial expectations.
Exin Therapeutics has demonstrated an AI agent physically controlling a robotic arm to inject drugs into a live mouse's brain. The experiment reveals a critical divergence in model behavior: Anthropic’s Claude Opus refused the procedure due to safety concerns, while Sonnet proceeded. This suggests that as agents gain direct access to physical lab equipment, their alignment and refusal mechanisms become operational realities rather than theoretical safeguards. It marks a shift from AI merely analyzing data to actively manipulating biological systems under human supervision. The team initially tested Claude Opus 5.5, but it halted the injection, citing potential harm. Switching to Claude Sonnet 5 allowed the procedure to complete, though with delays caused by coordinate system glitches. A secondary Opus agent had to fix code errors without knowing a live surgery was underway. Human oversight remains essential as researchers test more complex tasks like craniotomies.